Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Antisense & RNAi Therapeutics Market Today And What Is Its Future Size?

The market for antisense & RNAi therapeutics has seen substantial growth in the past few years. Its size is projected to increase from $1.75 billion in 2024 to $1.93 billion in 2025, with a compound annual growth rate (CAGR) of 10.2%. Several factors have propelled the growth during the historic period, such as increased funding, technological advancements, escalated healthcare spending, a surge in the aging population, and economic expansion in emerging markets.

The market size of antisense & RNAi therapeutics is projected to experience a fast-paced expansion in the forthcoming years, with an estimation to reach “$3.11 billion in 2029, recording a compound annual growth rate (CAGR) of 12.8%. The anticipated growth during the forecasting timeline can be connected to the broader healthcare accessibility, escalating cases of cancer, and growing demand for antisense and RNAi therapeutics in light of the COVID-19. Key trends set to shape the forecast period encompass concentrated endeavors towards R&D of RNA therapeutics targeting rare diseases, incorporation of nanoparticles, evolution of advanced antisense and RNAi therapeutics, and partnerships with other firms for product ingenuity and revenue growth.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

What Core Drivers Are Expected To Influence The Antisense & RNAi Therapeutics Market?

The antisense & RNAi therapeutics market is anticipated to grow due to the increasing incidences of coronary artery diseases, neurodegenerative disorders, and infectious diseases. Gene suppression methods such as RNA interference and antisense oligonucleotides are employed to treat various neurodegenerative conditions by correcting defective genes. To illustrate, a report released by the American Heart Association, a U.S. based entity, in January 2024 revealed that the age-adjusted death rate from cardiovascular diseases climbed to 233.3 per 100,000—marking a 4.0% increase compared to the prior year. Therefore, the escalating rates of numerous neurodegenerative and infectious diseases are likely to propel the expansion of the antisense & RNAi therapeutics market.

Which Segmentation Factors Are Critical In The Antisense & RNAi Therapeutics Market Analysis?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Are The Dominant Trends Currently Seen In The Antisense & RNAi Therapeutics Market?

Prominent businesses in the antisense & RNAi therapeutics market are employing strategic initiatives such as collaborations and partnerships to maintain their position in this fiercely competitive marketplace. The manoeuvre of strategic collaboration involves two or more companies joining forces to realise a shared purpose or goal. As an example, in January 2023, Orbit Discovery Limited, a US-based business that offers peptide discovery services, allied with SanegeneBio Inc., a UK-based company engaged in developing innovative RNAi-based medicines, for the identification of tissue-specific RNA therapeutic delivery for effective gene knockdown with the joint aim to expand their advanced RNAi therapeutics portfolio. This agreement includes the identification of probable hits and cell-based absorption studies, where Sanegene can opt to refine the potential hits resulting from the screening procedures, utilizing Orbit’s proprietary technology for prompt peptide lead discovery. The unique peptide display engine of Orbit Discovery facilitates the examination of extensive peptide libraries, resulting in quicker identification of pertinent peptide leads through affinity and functional screening.

Which Players Are Shaping The Competitive Landscape Of The Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model